Melbourne, July 30, 2009 (ABN Newswire) - Mesoblast Limited (ASX:MSB)(PINK:MBLTY) has entered the new financial year with sufficient cash reserves to meet its near-term clinical and commercial objectives. With A$16.5 million cash in hand at the end of June 2009, we can maintain the brisk pace of product development that has been the hallmark of your company since its public listing just 4.5 years ago.
